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ABSTRACT
Objectives: To evaluate the correlation between lymphovascular space invasion (LVSI) indicating lower uterine segment 
involvement (LUSI) in endometrioid endometrial cancer and lymph node metastasis based on the lymphatic drainage 
difference between the uterine corpus and the lower segment.
Material and methods: Patients who underwent staging surgery for endometrioid endometrial cancer between January 
2010 and January 2019 at our institution were reviewed. The clinicopathologic findings and LUSI status of the patients were 
compared with their LVSI and lymph node metastasis status.
Results: Of the 253 patients included in this study, 49 (19.4%) had LUSI. Among these patients, none of the 31 LVSI-negative 
patients had metastatic lymph node involvement. However, of the 18 LVSI-positive patients, half had metastatic lymph 
node involvement; this difference was significant (p < 0.05).
Conclusions: The significant correlation between LVSI and lymph node metastasis in LUSI-positive cases indicates that 
pathologists should also focus on LVSI findings in the frozen examination required for the decision of staging surgery in 
patients with endometrioid endometrial cancer limited to the uterus. This is especially important in patients with a lower 
uterine segment involvement.
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INTRODUCTION
Although endometrial cancer ranks eighth among the 
most common 15 cancers in women in terms of incidence, it 
ranks 13th for mortality. This is because, in developing coun-
tries, these cases are usually diagnosed at an early stage; 
thus, the survival rates are high following primary surgery 
[1]. However, there are studies showing that lymphovascular 
space invasion (LVSI), defined as tumour cell accumulation 
in the lymphatic and blood vessels close to the invasive 
margin [2], is an independent risk factor for lymph node 
metastasis, even in these early stage endometrial cancer 
cases [3–6]. Nevertheless, unlike myometrial invasion and 
histological grade, which indicate the risk of lymph node 
metastasis, LVSI has not yet been identified as a predictive 
factor in endometrioid endometrial cancers that are limited 
to the uterus [7, 8].
The characteristics of lymphatic drainage differ between 
the lower and the upper segments of the uterine corpus [9]. 
This suggests that, in the case of endometrial cancer, the 
location of the tumour in the uterus might be a factor that 
may affect the correlation between the LVSI and lymph 
node metastasis. This is the first study to investigate the 
correlation of LUSI and LVSI with lymph node involvement.
Objectives
The aim of this study was to determine the effect of 
tumour location on the correlation between LVSI and lymph 
node metastasis in endometrioid endometrial cancer pa-
tients undergoing staging surgery.
MATERIAL AND METHODS
The hospital records of 376 patients undergoing staging 
surgery for the diagnosis of endometrial cancer between 
1 January 2010 and 31 January 2019 were reviewed in this 
retrospective study. Ethics committee approval was obtained 
from our institution before the study started (11/2019).
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The study included patients whose final pathology was 
representative of pure endometrioid endometrial cancer 
and who had the information about tumour size, LVSI, and 
lower uterine segment involvement (LUSI) in their pathology 
report. Patients with non-endometrioid endometrial cancer, 
a mixed type histology (≥ 10 non-endometrioid compo-
nent), simultaneous malignancies, and with non-uterine 
metastasis in the intraoperative observational or frozen sec-
tion examination were excluded from the study. Cases with 
less than 11 pelvic lymph nodes and less than 3 para-aortic 
lymph nodes in the pathology report, defined as an insuf-
ficient number of lymph nodes in the literature [10, 11], were 
not included in the study (Fig. 1).
Demographic data and the presence of diabetes prov-
en by laboratory data (fasting plasma glucose of ≥ 126 or 
2nd-hour plasma glucose of ≥ 200 after 75 mg of oral glu-
cose) were obtained by reviewing the patient files [12]. Histo-
logic type [13] and grade, [14] tumour size (≤ 2 cm or > 2 cm), 
myometrial invasion percentage (< 50% or ≥ 50%), [15] LUSI 
(present or absent), and LVSI (present or absent) findings 
defined by the World Health Organization (WHO) and the In-
ternational Federation of Gynecology and Obstetrics (FIGO) 
criteria, number of lymph nodes removed and metastasis 
findings, peritoneal cytology finding (benign or malign),and 
adenomyosis finding were obtained by reviewing the pa-
thology reports. The stage of the disease was determined 
according to the FIGO 2009 criteria [16]. Cancer antigen 
(CA)-125 levels determined by the Roche E170 Modular 
System chemiluminescence method were grouped accord-
ing to the cut-off value (< 17.03 U/mL), which was chosen 
based on the laboratory reference value (< 35 U/mL) and 
the CA-125 mean value [17]. The LUSI and LVSI statuses of 
the cases along with patient age, lymph node metastatic 
involvement, tumour size, histological grade, CA-125 levels, 
presence of diabetes, and adenomyosis were compared.
LVSI was defined as the accumulation of tumour cells in 
the nearby lymphatic and blood vessels outside of the inva-
sive margin [2]. LUSI was defined as the presence of tumour 
invasion in the lower quadrant of the uterine corpus [18].
The data were expressed as mean ± standard deviation 
or number and percentage. The Chi-square and Fisher’s 
exact test were used to compare the categorical data, while 
the One-Way ANOVA test was used for comparisons of more 
than two independent variables. If normally distributed, the 
non-categorical data were compared using the Student’s 
t-test; if not, they were compared using the Mann-Whitney 
U test. All calculations were performed using SPSS (IBM Corp. 
Armonk, NY, USA) version 20.0 statistical software. A p value 
of < 0.05 was considered statistically significant.
RESULTS
The mean age of the 253 patients included in the study 
was 60.3 ± 9.8 years. The distribution of the number and 
mean age of the patients by LVSI, LUSI, and lymph node 
status is given in Table1. From the total cases, 42 (16.6%) 
had LVSI and 49 (19.4%) had LUSI. The distribution of the 
patients included in the study according to their LUSI and 
LVSI status is given in Table 2. A total of 19 (7.5%) patients 
had malignant metastases in the lymph nodes. The distri-
bution of lymph node metastases of patients according to 
Figure 1. Flow chart of exclusion criteria
Patients undergoing hysterectomy for endometrial cancer
376 cases
Pathology reports with no 
tumour diameter information
12 cases
Pathology reports without 
LUSI and LVSI knowledge
81 cases
Non-endometrioid type 
endometrial tumour
15 cases
Inadequate  
lymphadenectomy 
5 cases
Patients included in the study
253 cases
Intraoperative findings of extra-
-uterine invasion or metastasis
6 cases
Presence of concurrent 
malignancy
4 cases
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their LVSI and LUSI status is given in Table 3. Among the 
LUSI-positive cases, none of the 31 LVSI-negative cases had 
metastatic lymph node involvement; however, half of the 
18 LVSI-positive cases had metastatic lymph node involve-
ment. This difference was significant (p < 0.05). There was no 
significant correlation between the LUSI status and lymph 
node metastasis in LVSI-positive cases (p > 0.05). Lymph 
node metastases distribution of LUSI-positive patients by 
LVSI status is given in Table 4, and the distribution of lymph 
node metastases of LVSI-positive cases by LUSI status is 
given in Table 5. Abdominal irrigation cytology was reported 
as malignant in only 7 (2.8%) patients. Of the patients with 
malignant abdominal irrigation cytology, one had LVSI only, 
three had both LUSI and LVSI, and the remaining patients 
had neither LUSI nor LVSI. A preoperative CA-125 value was 
present only in 150 (59.3%) of patients included in the study. 
In order to approach the mean value of Ca-125 (22.50 U/mL) 
to 5% trimmed mean value (16.32 U/mL), 4 cases with CA-
125 above 130 U/mL were removed, then the calculation 
was performed and the mean value was found 17.03 ± 15.02. 
The comparison of the LVSI and LUSI status with the clinical 
and pathological data is presented in Table 6.
DISCUSSION
Our study is the first to investigate the correlation of 
LUSI and LVSI with lymph node involvement and the fac-
tors affecting this correlation in patients with endometrioid 
endometrial carcinoma. The most interesting finding in 
our study was that of the LUSI-positive cases, none of the 
31 LVSI-negative cases had metastatic lymph node involve-
Table 2. Case distribution according to LUSI and LVSI conditions
LUSI present n (%) LUSI absent n (%) P value
LVSI present LVSI absent LVSI present LVSI absent
< 0.05*
18 (36.7) 31 (63.3) 24 (11.8) 180 (88.2)
*Pearson chi-square 
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine segment involvement; n — number
Table 1. Number and age distribution of cases according to LVSI, LUSI, and lymph node status
LVSI LUSI Lymph node
Present Absent
P value T value
Present Absent
P value T value
Malign Benign
P value T value
n (%) 42 (16.6) 211 (83.4) 49 (19.4) 204 80.6) 19 (7.5) 234 (92.5)
Age
mean ± SD
64.1 ± 8.7 59.6 ± 9.8 0.005 -2.818 63.7 ± 10.3 59.5 ± 9.5 0.007 -2.730 67.2 ± 9.5 59.8 ± 9.6 0.001 -3.261
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine segment involvement; n — number; SD — standard deviation
Table 4. LVSI and lymph node metastasis in LUSI-positive patients
LVSI
n (%)
Present
Lymph nodes 
metastasis n (%)
P value
Absent
Present 18 (36.7) 9 (50.0) 9 (50.0)
< 0.05*Absent 31 (63.3) 0 (0) 31 (100)
*Fisher’s exact test 
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine 
segment involvement; n — number
Table 3. Distribution of lymph node metastasis cases according to LUSI and LVSI status
Lymph nodes
n (%)
LVSI n (%)
P value
LUSI n (%)
P value
Present Absent Present Absent
Malignant
19 (7.5)
17 (40.5) 2 (0.9)
< 0.05*
9 (18.4) 10 (4.9)
< 0.05*
Benign
234 (92.5)
25 (59.5) 209 (99.1) 40 (81.6) 194 (95.1)
*Fisher’s exact test 
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine segment involvement; n — number
Table 5. LUSI and lymph node metastasis in LVSI-positive patients
LUSI
n (%)
Present
Lymph nodes 
metastasis n (%)
P value
Absent
Present 18 (42.9) 9 (50.0) 9 (50.0)
> 0.05*Absent 24 (57.1) 8 (33.3) 16 (66.7)
*Pearson chi-square 
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine 
segment involvement; n — number
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ment. However, half of the 18 LVSI-positive cases did have 
metastatic lymph node involvement (p < 0.05).
There is very little literature on the correlation between 
LUSI and LVSI. Only Erkaya et al. have investigated the effects 
of LUSI on survival in endometrial cancer. They examined the 
effects of LUSI and LVSI as comorbidities on lymph node me-
tastasis and reported that the tumours may have different 
clinicopathological characteristics due to the differences in 
lymphatic drainage between the lower and upper segments 
of the uterus in LUSI-positive patients [19].
Gemer et al. (2009) [20] reported a significant correlation 
between LUSI and LVSI. In a study by Miyoshi et al. (2018) [21] 
investigating the prognostic characteristics of lower uterine 
segment tumors, it was observed that though not signifi-
cantly, LVSI was more common in the primary tumours of 
the lower uterine segment. The correlation between the 
location of the primary tumour and lymph node metastasis 
was found as significant in the same study. Both positive 
LUSI and LVSI were significantly associated with lymph node 
metastasis in our study as well.
Table 6. Distribution of the factors investigated by the LVSI and LUSI status
Investigated factors
n (%)
Absent
LVSI
n (%) P value
Absent
LUSI
n (%) P value
Present Present
Diabetes Mellitus
Absent
104 (41.1) 91 (87.5) 13 (12.5)
0.143*
83 (79.8) 21 (20.2)
0.782*Present
149 (58.9) 120 (80.5) 29 (19.5) 121 (81.2) 28 (18.8)
Adenomyosis
Absent
213 (84.2) 176 (82.6) 37 (17.4)
0.447*
169 (79.3) 44 (20.7)
0.231*Present
40 (15.8) 35 (87.5) 5 (12.5) 35 (87.5) 5 (12.5)
Tumour diameter
≤ 2 cm
107 (42.3) 102 (95.3) 5 (4.7)
< 0.05*
100 (93.5) 7 (6.5)
< 0.05*> 2 cm
146 (57.7) 109 (74.7) 37 (25.3) 104 (71.2) 42 (28.8)
Ca-125
U/mL
< 20
109 (72.7) 96 (88.1) 13 (11.9)
0.002*
96 (88.1) 13 (11.9)
0.001*> 20
41 (27.3) 27 (65.9) 14 (34.1) 26 (63.4) 15 (36.6)
< 35
132 (88.0) 114 (86.4) 18 (13.6)
0.001ⱡ
113 (85.6) 19 (14.4)
0.001ⱡ> 35
18 (12.0) 19 (50.0) 9 (50.0) 9 (50.0) 9 (50.0)
Histologic grade
1
147 (58.1) 141 (95.9) 6 (4.1)
< 0.05ˠ
127 (86.4) 20 (13.6)
0.013ˠ
2
90 (35.6) 62 (68.9) 28 (31.1) 67 (74.4) 23 (25.6)
3
16 (6.3) 8 (50.0) 8 (50.0) 10 (62.5) 6 (37.5)
MI
< 50%
165 (65.2)
158 (95.8) 7 (4.2)
< 0.05*
150 (90.9) 15 (9.1)
< 0.05*≥ 50%
88 (34.8)
53 (60.2) 35 (39.8) 54 (61.4) 34 (38.6)
Stage
IA
165 (65.2)
150
(90.9)
15
(9.1)
< 0.05ˠ
158
(95.8)
7
(4.2)
< 0.05ˠ
IB
59 (23.3)
44
(74.6)
15
(25.4)
43
(72.9)
16
(27.1)
II
10 (4.0)
0
(0)
10
(100)
8
(80.0)
2
(20.0)
IIIC
19 (7.5)
10
(52.6)
9
(47.4)
2
(10.5)
17
(89.5)
*Pearson chi-square, ⱡFisher’s exact test, ˠOne-Way ANOVA 
LVSI — lymphovascular space invasion; LUSI — indicating lower uterine segment involvement; MI — myometrial invasion; n — number
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the patients without involvement in our study. Most of the 
studies in the literature did not find any significant correla-
tion between age and LUSI [19, 20, 31, 32]. Considering the 
correlation between patient age and LVSI status, it is seen 
that there are publications which found both significant [3, 
33] and insignificant [27] correlations.
Significant correlations have been reported between 
tumour size, [34, 19] histological grade [19, 33], and myome-
trial invasion [19, 20, 33]. These, along with the LUSI and LVSI 
statuses of patients, affect the decision to proceed with intra-
operative lymphadenectomy in endometrial cancer surgery. 
Furthermore, these correlations were also present in our study.
The limitation of this study is the lack of sufficient in-
formation on tumour size, LUSI, and LVSI in some pathol-
ogy reports, especially between 2010 and 2011. To ensure 
the exclusion of fewer cases in future studies, a correlation 
should be established between gynaecological oncologists 
and pathologists, particularly with regard to the content of 
the pathology report.
Although a retrospective design was used in this study, 
we believe that this was compensated for by the fact that 
1) the operations were performed by experienced gynae-
cological oncologists in a single institution, 2) an adequate 
number of lymph nodes were obtained from all patients 
undergoing staging surgery, and 3) the operation materials 
were evaluated by the same gynaecological pathology team.
CONCLUSIONS
We believe that, regarding lymph node metastasis in 
endometrioid endometrial cancer, LUSI positivity signals the 
necessity to focus on LVSI. Therefore, in such cases, surgeons 
should ask for LUSI and LVSI findings from pathologists, in 
order to facilitate decisions regarding staging surgery.
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